Titre : C1 Inhibiteur

C1 Inhibiteur : Questions médicales fréquentes

Termes MeSH sélectionnés :

Factor XII Deficiency
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "C1 Inhibiteur : Questions médicales les plus fréquentes", "headline": "C1 Inhibiteur : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les C1 Inhibiteur : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-06", "dateModified": "2025-05-01", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "C1 Inhibiteur" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines inhibitrices de la fraction C1 du complément", "url": "https://questionsmedicales.fr/mesh/D003174", "about": { "@type": "MedicalCondition", "name": "Protéines inhibitrices de la fraction C1 du complément", "code": { "@type": "MedicalCode", "code": "D003174", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.872.140" } } }, "about": { "@type": "MedicalCondition", "name": "C1 Inhibiteur", "alternateName": "Complement C1 Inhibitor Protein", "code": { "@type": "MedicalCode", "code": "D050718", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Henriette Farkas", "url": "https://questionsmedicales.fr/author/Henriette%20Farkas", "affiliation": { "@type": "Organization", "name": "Department of Internal Medicine and Haematology, Hungarian Angioedema Center of Reference and Excellence, Semmelweis University, Szentkiralyi u. 46, Budapest, 1088, Hungary. farkas.henriette@med.semmelweis-univ.hu." } }, { "@type": "Person", "name": "Lilian Varga", "url": "https://questionsmedicales.fr/author/Lilian%20Varga", "affiliation": { "@type": "Organization", "name": "Department of Internal Medicine and Haematology, Hungarian Angioedema Center of Reference and Excellence, Semmelweis University, Szentkiralyi u. 46, Budapest, 1088, Hungary." } }, { "@type": "Person", "name": "Anastasios E Germenis", "url": "https://questionsmedicales.fr/author/Anastasios%20E%20Germenis", "affiliation": { "@type": "Organization", "name": "Department of Immunology and Histocompatibility, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece." } }, { "@type": "Person", "name": "Andrea Zanichelli", "url": "https://questionsmedicales.fr/author/Andrea%20Zanichelli", "affiliation": { "@type": "Organization", "name": "Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Via G.B. Grassi 74, 20157 Milan, Italy." } }, { "@type": "Person", "name": "Chiara Suffritti", "url": "https://questionsmedicales.fr/author/Chiara%20Suffritti", "affiliation": { "@type": "Organization", "name": "ASST-Fatebenefratelli-Sacco, Milan, Italy. chiarasuffritti@gmail.com." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Factors XI and XII in extracorporeal membrane oxygenation: longitudinal profile in children.", "datePublished": "2023-11-04", "url": "https://questionsmedicales.fr/article/38193071", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.rpth.2023.102252" } }, { "@type": "ScholarlyArticle", "name": "Coagulation factor XII contributes to renin activation, heart failure progression, and mortality.", "datePublished": "2024-09-12", "url": "https://questionsmedicales.fr/article/39314400", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1101/2024.09.06.611753" } }, { "@type": "ScholarlyArticle", "name": "Factor XII promotes the thromboinflammatory response in a rat model of venoarterial extracorporeal membrane oxygenation.", "datePublished": "2023-09-07", "url": "https://questionsmedicales.fr/article/37683721", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jtcvs.2023.08.045" } }, { "@type": "ScholarlyArticle", "name": "A clinical evaluation of patients with known mutations (plasminogen and factor XII) with a focus on prophylactic treatment.", "datePublished": "2023-12-12", "url": "https://questionsmedicales.fr/article/38086754", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/09546634.2023.2290362" } }, { "@type": "ScholarlyArticle", "name": "Increased factor XI but not factor XII is associated with enhanced inflammation and impaired fibrin clot properties in patients with eosinophilic granulomatosis with polyangiitis.", "datePublished": "2023-12-04", "url": "https://questionsmedicales.fr/article/38079326", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.55563/clinexprheumatol/kzi1u4" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines inhibitrices de la fraction C1 du complément", "item": "https://questionsmedicales.fr/mesh/D003174" }, { "@type": "ListItem", "position": 5, "name": "C1 Inhibiteur", "item": "https://questionsmedicales.fr/mesh/D050718" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : C1 Inhibiteur - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur C1 Inhibiteur", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-01", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur C1 Inhibiteur", "description": "Comment diagnostiquer une déficience en C1 inhibiteur ?\nQuels tests sont utilisés pour évaluer le C1 inhibiteur ?\nQuels symptômes indiquent un problème de C1 inhibiteur ?\nLe diagnostic nécessite-t-il une consultation spécialisée ?\nPeut-on diagnostiquer par des antécédents familiaux ?", "url": "https://questionsmedicales.fr/mesh/D050718?mesh_terms=Factor+XII+Deficiency&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur C1 Inhibiteur", "description": "Quels sont les symptômes d'une carence en C1 inhibiteur ?\nLes symptômes varient-ils selon l'âge ?\nLes œdèmes sont-ils toujours présents ?\nY a-t-il des symptômes associés à des infections ?\nLes symptômes peuvent-ils être confondus avec d'autres maladies ?", "url": "https://questionsmedicales.fr/mesh/D050718?mesh_terms=Factor+XII+Deficiency&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur C1 Inhibiteur", "description": "Comment prévenir les crises d'œdème ?\nLes patients doivent-ils éviter certains aliments ?\nLe stress influence-t-il les crises ?\nDes vaccinations sont-elles recommandées ?\nLes patients doivent-ils porter un bracelet médical ?", "url": "https://questionsmedicales.fr/mesh/D050718?mesh_terms=Factor+XII+Deficiency&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur C1 Inhibiteur", "description": "Quels traitements sont disponibles pour la carence en C1 inhibiteur ?\nLe traitement préventif est-il nécessaire ?\nLes corticostéroïdes sont-ils efficaces ?\nY a-t-il des traitements expérimentaux ?\nComment gérer une crise aiguë ?", "url": "https://questionsmedicales.fr/mesh/D050718?mesh_terms=Factor+XII+Deficiency&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur C1 Inhibiteur", "description": "Quelles sont les complications possibles de la carence en C1 inhibiteur ?\nLes œdèmes peuvent-ils entraîner des complications graves ?\nY a-t-il un risque accru de maladies auto-immunes ?\nLes complications peuvent-elles affecter la qualité de vie ?\nLes complications nécessitent-elles une surveillance régulière ?", "url": "https://questionsmedicales.fr/mesh/D050718?mesh_terms=Factor+XII+Deficiency&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur C1 Inhibiteur", "description": "Quels sont les facteurs de risque de carence en C1 inhibiteur ?\nLes infections fréquentes sont-elles un facteur de risque ?\nLe sexe influence-t-il le risque de carence ?\nL'âge joue-t-il un rôle dans le risque ?\nLes facteurs environnementaux influencent-ils le risque ?", "url": "https://questionsmedicales.fr/mesh/D050718?mesh_terms=Factor+XII+Deficiency&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une déficience en C1 inhibiteur ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un dosage sanguin du C1 inhibiteur et des tests fonctionnels sont nécessaires." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer le C1 inhibiteur ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent le dosage du C1 inhibiteur et l'évaluation de l'activité fonctionnelle." } }, { "@type": "Question", "name": "Quels symptômes indiquent un problème de C1 inhibiteur ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des œdèmes, des douleurs abdominales et des éruptions cutanées." } }, { "@type": "Question", "name": "Le diagnostic nécessite-t-il une consultation spécialisée ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une consultation en immunologie ou en allergologie est souvent recommandée." } }, { "@type": "Question", "name": "Peut-on diagnostiquer par des antécédents familiaux ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de symptômes similaires peuvent orienter le diagnostic." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une carence en C1 inhibiteur ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des œdèmes récurrents, des douleurs abdominales et des éruptions cutanées." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon l'âge ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent apparaître à tout âge, mais souvent durant l'enfance ou l'adolescence." } }, { "@type": "Question", "name": "Les œdèmes sont-ils toujours présents ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Non, les œdèmes peuvent être intermittents et ne pas se manifester constamment." } }, { "@type": "Question", "name": "Y a-t-il des symptômes associés à des infections ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des infections peuvent exacerber les symptômes liés à la carence en C1 inhibiteur." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils être confondus avec d'autres maladies ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent être similaires à ceux d'autres troubles allergiques ou auto-immuns." } }, { "@type": "Question", "name": "Comment prévenir les crises d'œdème ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les déclencheurs connus et suivre un traitement préventif régulier." } }, { "@type": "Question", "name": "Les patients doivent-ils éviter certains aliments ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains aliments peuvent déclencher des réactions, il est conseillé de les identifier." } }, { "@type": "Question", "name": "Le stress influence-t-il les crises ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut être un facteur déclenchant pour certaines personnes." } }, { "@type": "Question", "name": "Des vaccinations sont-elles recommandées ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les vaccinations peuvent aider à prévenir les infections qui aggravent les symptômes." } }, { "@type": "Question", "name": "Les patients doivent-ils porter un bracelet médical ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un bracelet médical peut alerter en cas d'urgence liée à la carence en C1 inhibiteur." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour la carence en C1 inhibiteur ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des concentrés de C1 inhibiteur et des médicaments anti-inflammatoires." } }, { "@type": "Question", "name": "Le traitement préventif est-il nécessaire ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un traitement préventif peut être recommandé pour éviter les crises d'œdème." } }, { "@type": "Question", "name": "Les corticostéroïdes sont-ils efficaces ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les corticostéroïdes peuvent réduire l'inflammation, mais ne traitent pas la cause sous-jacente." } }, { "@type": "Question", "name": "Y a-t-il des traitements expérimentaux ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des thérapies géniques et des traitements ciblés sont en cours d'évaluation." } }, { "@type": "Question", "name": "Comment gérer une crise aiguë ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "L'administration rapide de C1 inhibiteur est essentielle lors d'une crise aiguë." } }, { "@type": "Question", "name": "Quelles sont les complications possibles de la carence en C1 inhibiteur ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des œdèmes sévères, des infections et des douleurs chroniques." } }, { "@type": "Question", "name": "Les œdèmes peuvent-ils entraîner des complications graves ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des œdèmes laryngés peuvent provoquer des difficultés respiratoires potentiellement mortelles." } }, { "@type": "Question", "name": "Y a-t-il un risque accru de maladies auto-immunes ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients peuvent avoir un risque accru de développer des maladies auto-immunes." } }, { "@type": "Question", "name": "Les complications peuvent-elles affecter la qualité de vie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes chroniques et les crises peuvent significativement altérer la qualité de vie." } }, { "@type": "Question", "name": "Les complications nécessitent-elles une surveillance régulière ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une surveillance régulière est essentielle pour gérer les complications potentielles." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque de carence en C1 inhibiteur ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux et certaines mutations génétiques augmentent le risque." } }, { "@type": "Question", "name": "Les infections fréquentes sont-elles un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les infections récurrentes peuvent exacerber les symptômes chez les patients." } }, { "@type": "Question", "name": "Le sexe influence-t-il le risque de carence ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la carence en C1 inhibiteur est plus fréquente chez les femmes que chez les hommes." } }, { "@type": "Question", "name": "L'âge joue-t-il un rôle dans le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque peut augmenter avec l'âge, bien que les symptômes apparaissent souvent plus tôt." } }, { "@type": "Question", "name": "Les facteurs environnementaux influencent-ils le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains facteurs environnementaux peuvent déclencher des crises chez les individus sensibles." } } ] } ] }

Sources (10000 au total)

Factors XI and XII in extracorporeal membrane oxygenation: longitudinal profile in children.

Extracorporeal membrane oxygenation (ECMO) is used in children with cardiopulmonary failure. While the majority of ECMO centers use unfractionated heparin, other anticoagulants, including factor XI an... This study aimed to describe the longitudinal profile of FXI and FXII antigenic levels and function before, during, and after ECMO in children.... This is a prospective observational study in neonatal and pediatric patients with ECMO (<18 years). All patients with venoarterial ECMO and with sufficient plasma volume collected before ECMO, on day ... Sixteen patients were included in this study. Mean FXI and FXII antigenic levels (U/mL) changed from 7.9 and 53.2 before ECMO to 6.0 and 34.5 on day 3 and they recovered to 8.8 and 39.4, respectively,... This study provides the first insights into changes of the contact pathway in children undergoing ECMO. FXI and FXII antigen and function change during ECMO. Results from this study can be used as sta...

Factor XII promotes the thromboinflammatory response in a rat model of venoarterial extracorporeal membrane oxygenation.

Factor XII (FXII) is a multifunctional protease capable of activating thrombotic and inflammatory pathways. FXII has been linked to thrombosis in extracorporeal membrane oxygenation (ECMO), but the ro... FXII-deficient (FXII... FXII... FXII initiates hemostatic system activation and key inflammatory sequelae in ECMO, suggesting that therapies targeting FXII could limit both thromboembolism and inopportune inflammatory complications ...

A clinical evaluation of patients with known mutations (plasminogen and factor XII) with a focus on prophylactic treatment.

Hereditary angioedema with normal C1-inhibitor (HAE-nC1-INH) is a rare genetic disease. The symptoms can resemble other forms of hereditary angioedema (HAE), but the specific laboratory values are inc... An analysis of all patients with HAE-nC1-INH was carried out in a certified angioedema treatment center in southern Germany. Only patients with a confirmed HAE-nC1-INH mutation were included. The impa... Eighteen patients were included: two families with a factor XII mutation and seven families with a plasminogen mutation. All individuals received icatibant for on-demand therapy-efficient treatment re... This is one of the first descriptions of the clinical outcomes as a response to prophylactic treatment with lanadelumab in HAE-nC1-INH patients with a known mutation. The therapeutic management of HAE...

Increased factor XI but not factor XII is associated with enhanced inflammation and impaired fibrin clot properties in patients with eosinophilic granulomatosis with polyangiitis.

In eosinophilic granulomatosis with polyangiitis (EGPA) a prothrombotic state, including formation of denser fibrin networks with reduced lysability has been observed. Little is known about the intrin... In 34 consecutive EGPA patients with remission we assessed FXI and FXII levels along with plasma fibrin clot permeability (Ks), fibrin clot morphology using scanning electron microscopy, and efficienc... Increased FXI level (>130%, the upper reference limit) was found in 8 (23.5%) patients. Compared to patients with FXI levels ≤130%, those with increased FXI had higher eosinophil count (+365%) and red... To our knowledge, this study is the first to show association between FXI and a prothrombotic state in EGPA. Given clinical trials on FXI inhibition as an antithrombotic option, our findings suggest t...

Pharmacological targeting of coagulation factors XII and XI by monoclonal antibodies reduces thrombosis in nitinol stents under flow.

Cardiovascular implantable devices, such as vascular stents, are critical to the treatment of cardiovascular diseases. However, their success is dependent on robust and often long-term antithrombotic ... To study the efficacy of monoclonal antibody targeting factors (F) XII and XI of the contact pathway in preventing vascular device-related thrombosis.... The effects of inhibition of FXII and FXI using function-blocking monoclonal antibodies were examined in a non-human primate model of nitinol stent-related thrombosis under arterial and venous flow co... We found that function-blocking antibodies of FXII and FXI reduced markers of stent-induced thrombosis in vitro and ex vivo. However, FXI inhibition resulted in more effective mitigation of thrombosis... This work provides further support for the translation of contact pathway of coagulation inhibitors for their adjunctive clinical use with cardiovascular devices....